Is There a Biological Basis for Treatment of Fibrodysplasia Ossificans Progressiva with Rosiglitazone? Potential Benefits and Undesired Effects

類似資料

• Is There a Biological Basis for Treatment of Fibrodysplasia Ossificans Progressiva with Rosiglitazone? Potential Benefits and Undesired Effects
  著者:: Renata Bocciardi, 等
  出版事項: (2010-01-01)
• Genomic Context and Mechanisms of the ACVR1 Mutation in Fibrodysplasia Ossificans Progressiva
  著者:: Ravazzolo, Roberto, 等
  出版事項: (2021)
• The Horizon of a Therapy for Rare Genetic Diseases: A “Druggable” Future for Fibrodysplasia Ossificans Progressiva
  著者:: Cappato, Serena, 等
  出版事項: (2018)
• Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements
  著者:: Bocciardi, Renata, 等
  出版事項: (2009)
• Identification and characterization of regulatory elements in the promoter of ACVR1, the gene mutated in Fibrodysplasia Ossificans Progressiva
  著者:: Giacopelli, Francesca, 等
  出版事項: (2013)